I'm long DNDN (Prostate Cancer), SQNM, & (VVUS/ARNA-Obesity Play). Are there any others about to pop? I had BCRX, but missed the jump up last week. I'm looking for a few more opportunities like this one. I'm not a player like some of you. Just an amateur investor with some play money.
Not recommending to buy, but this one worked real well for me......
Bought API in late 2001.....
Sold in in early 2004 for about 500% gain......
FYI...it's at the very same price now that I bought it in 2001.......
It could do a Repeat......
...or even better...do what it did in 2000.....
Check it out....it could surprise many soon........
I am looking real strong again at getting in..........
Agria, symbol GRO - Chinese AG stock currently trading below cash position of $2.78 per share and at roughly 1/2 of book value. Delayed Q4 report due to some minor allegations by an ex-employee and have hired an independent firm to investigate. Company is profitable, in China, has 3 Ag platforms to build off of...stock is a short-term double IMO and I could see $10+ once they get back on track. FYI, I'm slowly accumulating here at the $2-$2.25 level and with a Buy Stop just above $2.50, which would be a break above 50 DMA and extremely bullish...
Barclay put out this report. There are 3 releases from them. Price target has been 11 for 2 years, by the way.
July 28, 2009
ARIAD Pharmaceuticals (ARIA - US$ 2.45) 1-Overweight
Improving Visibility for Ridaforolimus
We are maintaining our 1-Overweight on ARIA
following release of prelimin phase I/II data for
ridaforolimus in combination with Herceptin and
Avastin. Early data suggests potential synergy
with Her2 and VEGF targeted biologics and could
support expanded opportunity into mCRC, NSCLC
and mBC in the future. Near term focus remains
on the phase III SUCCEED study in Sarcoma
where we believe that prior mTOR inhibitor
success suggests a likely benefit for ridaforolimus.
ARIA reported prelimin. phase I/II data for
radiforolimus in combination with Herceptin and
Avastin. Phase II data for ridaoforolimus +
Herceptin in n=28 pts with Herceptin resistant
mBC suggests an 18% ORR (5/28 PR), 35% CBR
rate with 54% (15/28) free of progression at
present. Phase I data for ridaforolimus+Avastin in
n=17 pts with advanced solid tumors suggests
35% CBR rate with no undue safety issues.
With further detail expected at ESMO in Sept. we
are encouraged by increasing breadth of
ridaforolimus development and would note
separately completion of enrollment of a n=150
patient Casodex combination trial in HRPC which
could support more meaningful data in 2010.